Preparations containing ceraracertib

A ceraracertib formulation with dibasic calcium phosphate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and magnesium stearate addresses compliance and manufacturability issues, enhancing stability and uniform drug release for effective cancer therapy.

JP7873676B2Active Publication Date: 2026-06-12ASTRAZENECA AB
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023558276
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-03-22
Filing Date
2022-03-21
Publication Date
2026-06-12
Estimated Expiration
2042-03-21

Smart Images

  • Figure 0007873676000007
    Figure 0007873676000007
  • Figure 0007873676000008
    Figure 0007873676000008
  • Figure 0007873676000009
    Figure 0007873676000009
Patent Text Reader

Abstract

A pharmaceutical formulation is described that includes selarasertib, dibasic calcium phosphate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Quinoline compound for combined treatment on breast cancer

    CN112043831A

  • Orally disintegrable tablet

    JP2020164517A

  • Morpholino pyrimidines and their use in therapy

    WO2011154737A1

  • Combination of BUB1 and ATR inhibitors

    WO2018206547A1